SuperworthGain Therapeutics shares outstanding GANX
Diluted shares outstanding, averaged over each quarter, from 2020.
- Latest quarter, to Jun 30, 2026
- 42.9M
- On a year earlier
- +41.3%
- more shares
Gain Therapeutics had 42.9M diluted shares outstanding on average in Q2 FY26, the quarter to Jun 30, 2026.
That is 41.3% more than a year earlier, so each share owns a little less of the company.
Shares outstanding over time
Fiscal year by fiscal year
| Fiscal year | Shares, fourth quarter | Change |
|---|---|---|
| FY2025 | 37.8M | +36% |
| FY2024 | 27.7M | +85% |
| FY2023 | 15M | +26% |
| FY2022 | 11.9M | +0% |
| FY2021 | 11.9M | +235% |
| FY2020 | 3.5M | n/a |
Each fiscal year is the twelve months to its fourth quarter, shown as the fourth quarter's average share count.
Quarter by quarter
| Quarter | Ended | Shares outstanding | On a year earlier |
|---|---|---|---|
| Q2 FY26 | 42.9M | +41% | |
| Q1 FY26 | 42.2M | +47% | |
| Q4 FY25 | 37.8M | +36% | |
| Q3 FY25 | 35M | +32% | |
| Q2 FY25 | 30.3M | +58% | |
| Q1 FY25 | 28.7M | +60% | |
| Q4 FY24 | 27.7M | +85% | |
| Q3 FY24 | 26.5M | +109% | |
| Q2 FY24 | 19.2M | +55% | |
| Q1 FY24 | 18M | +51% | |
| Q4 FY23 | 15M | +26% | |
| Q3 FY23 | 12.7M | +7% |
What the shares outstanding tells you
Diluted shares outstanding, averaged over the period. Fewer shares means each one owns more of the company.
A falling count usually means buybacks. A rising one means stock pay, acquisitions paid in shares or new shares sold.
More on Gain Therapeutics
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.